Mavenir Leads an Open RAN Ecosystem
Mavenir, focused on transforming mobile network economics for communications service providers (CSPs), is announcing an Open RAN partner ecosystem that provides more options and makes it easy for operators to deploy an innovative, flexible Cloud-based Open RAN solution. Mavenir will act as the End-to-End systems integrator simplifying the engagement for operators and creating an offering that is on par with the traditional, hardware centric proprietary vendors.
Ecosystem partners include MTI, Tecore Networks, Baicells, NEC, AceAxis, KMW, Benetel, CommScope, Blue Danube Systems and Airrays.
“Mavenir has always been extremely active in promoting open interfaces as we believe it is in the interest of the CSPs and the overall industry. We will continue to support any effort in the direction of cloud-based architectures and virtualized solutions,” said Pardeep Kohli, President and CEO of Mavenir. “The formation of this ecosystem essentially creates a challenger to the traditional radio vendors. Mavenir would like to encourage any other player to support this effort which will result in a significant disruptive game changer as operators continue to seek a new economic model in a world where a traditional, hardware-based approach is no longer a viable option.”
“This Open RAN ecosystem announcement expands the addressable market for Open RAN solutions,” said Daryl Schoolar, Practice Leader, Service Provider Infrastructure and Software at Ovum. “The ecosystem partners allow for addressing a greater variety of deployment scenarios. End-to-end solution integration makes it easier for smaller operators to deploy these solutions as Mavenir will take on the responsibility of interoperability testing and multi-vendor integration. Smaller operators can lack the internal resources to deploy and manage a multi-vendor network.”
“Global mobile transformation is being defined by 5G, IOT, and subscriber demand for exponential capacity driving new economics and ecosystems, as a partner with Mavenir we are excited to be at the forefront driving a software and open ecosystem,” said Mark Pinto, CEO of Blue Danube.
“The xRAN interoperability testing between Baicells and Mavenir proves that the future of 5G has arrived,” said Minchul Ho, Vice-President of Vertical Sales, Baicells. “The Cloud RAN architecture provides operators several benefits including reduced opex from maintenance, economies of scale efficiencies and vast improved performance due to greater coordination among cells.”
“Achieving seamless Interoperability whilst providing a high level of system flexibility presents a significant challenge to both the RRU vendor and CSP community alike,” said Adrian O’Connor, CEO of Benetel. “However, with the help of these disruptive ecosystem partners and leaders like Mavenir, we will realize an end to end solution in the coming months.”
Interoperability testing has already been conducted based on the xRAN Option 7.2 split specification. Recently, the full xRAN (now ORAN) specifications have been officially released containing the management plane (M-plane), for which Mavenir significantly contributed, making this a complete open specification. Mavenir continues to test the latest version of the Option 7.2 split with the ecosystem partners, who are committed to the Open RAN community and making their solutions commercially available.
This approach is now being favored by Operators who want to embrace Open RAN as it allows the deployment of open market (whitebox) remote radio unit (RRUs) to interwork with the virtualized cloud base band unit (vBBU) over ethernet fronthaul (FH). With this, CSPs can break the stranglehold of closed proprietary specifications and the need to implement dark fiber for RRU fronthaul, which could pose significant economical burdens in some countries. They can continue to provide fronthaul and backhaul in the traditional ways like microwaves and IP/MPLS technologies.
Mavenir is purpose-built to redefine mobile network economics for Communication Service Providers (CSPs). Our innovative solutions pave the way to 5G with 100% software-based, end-to-end, Cloud Native network solutions. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC and Cloud RAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 130 countries, serving over 50% of the world’s subscribers.
We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation and revenue protection. Learn more at mavenir.com.
Mavenir, the M logo, and Cloud Range are trademarks owned by Mavenir Systems, Inc.
Copyright © 2018 Mavenir Systems, Inc. All Rights Reserved.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New data show first-line triplet regimen of pembrolizumab, Herzuma ® (biosimilar trastuzumab) and chemotherapy are effective in treatment of HER2-positive advanced gastric cancer29.5.2020 01:01:00 CEST | Press release
Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma®(biosimilar trastuzumab) and chemotherapy is effective in patients with HER2-positive advanced gastric cancer (AGC). The PANTHERA trial (a phase Ib/II study of first line pembrolizumab in combination with trastuzumab, capecitabine, and cisplatin in HER2-positive gastric cancer), sponsored by Celltrion Inc. and MSD, is investigating the potential of a first-line immunotherapy/chemotherapy combination with biosimilar trastuzumab. This is in light of a growing body of evidence that the immune system contributes to the therapeutic effects of monoclonal antibodies such as biosimilar trastuzumab in treating solid tumours.1 A total of 43 patients were treated with a median follow up of 18 months. Patients were treated with pembrolizumab 200mg via IV infusion D1,biosimilar trastuzumab 6mg/kg (after 8mg/kg load) D1, capecitabine 1000mg/m2 bid D1-D14 a
European Commission Releases Takeda From Commitment to Divest Shire’s Pipeline Compound SHP64729.5.2020 01:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announces that on May 28, the European Commission (the “EC”) has released Takeda from the obligation to divest the pipeline compound SHP647 and certain associated rights (“SHP647”), a commitment that was provided by Takeda to secure regulatory clearance of its acquisition of Shire plc (“Shire”). Takeda will discontinue the current SHP647 clinical trial program, and it will be providing all eligible trial participants with the opportunity to have continued access to SHP647 in a post-trial access (“PTA”) study. In addition, subject to obtaining trial participant consents and the satisfaction of regulatory and ethical considerations, Takeda will make SHP647 clinical trial data and biosamples available to the scientific community through the Crohn’s & Colitis Foundation (“Foundation”). Takeda announced on November 20, 2018, that the EC approved its proposed acquisition of Shire (the “Acquisition”). The EC’s appr
Jefferies' Clients, Employees and Shareholders Contribute $9,250,000 to Over 85 Charities for Coronavirus Relief in Memory of Peg Broadbent28.5.2020 18:02:00 CEST | Press release
Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease. Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000. “We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charit
JRJ Group Announces Sale of ETX Capital to Guru Capital28.5.2020 15:30:00 CEST | Press release
JRJ Group, a leading international private equity investment firm focused on the financial services sector and growth situations, is pleased to announce that it has agreed to terms for the sale of ETX Capital, one of the fastest growing international providers of multi-asset CFDs and spread betting products, to a fund associated with Guru Capital, a Switzerland-based private equity firm with specific experience in the CFD space. Terms of the transaction were not disclosed. Roger Nagioff, Founding Partner of JRJ Group, said, “During JRJ’s ownership, we have invested in bolt-on acquisitions and enhanced the technology of the firm. We are delighted with the strength and resilience of the platform we have built, alongside the management team and employees, and we wish the enterprise every success in its next stage of growth.” “We are grateful of JRJ Group’s support, and we look forward to growing the business with the Guru Capital team, who have substantial experience in the CFD sector,” s
eLichens Launches eStore for US and EU Markets28.5.2020 15:00:00 CEST | Press release
French start-up eLichens has launched its online store last week. eLos, for eLichens Outdoor Station, can now be purchased online by US and EU customers. Japan and other areas will soon join the list. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005117/en/ (Photo: Business Wire) eLos is a wireless, solar-powered air quality station. eLos provides citizens, communities and organizations the most accurate and complete real-time data about air quality, wherever they need it. Visit the store and learn more about eLos : https://www.elichens.com/store/elos View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005117/en/Contact information Marc Attia, email@example.com
SAB Biotherapeutics Confirms Neutralizing Antibodies to SARS-CoV-2 and Begins Clinical Manufacturing of Novel COVID-19 Therapeutic Candidate28.5.2020 14:24:00 CEST | Press release
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, today announced in vitro data demonstrating that SAB-185, its COVID-19 therapeutic candidate, has highly-potent neutralizing antibodies to SARS-CoV-2 that are four times higher than the most potent human convalescent plasma serum sample evaluated. The company also announced that they initiated manufacturing of SAB-185 on May 25 to support the next phase of clinical development for its potential COVID-19 therapeutic, still on track to begin human trials in early summer. “These data indicate this human polyclonal antibody therapeutic has potent neutralizing activity against live SARS-CoV-2. The neutralizing titers of SAB-185 are significantly higher than those of the most potent plasma of recovered COVID-19 patients we’ve been able to source,” said William B. Klimstra, PhD Associate Professor of Microbio